Neoadjuvant Darovasertib in Primary Uveal Melanoma

To join this study, you must have a type of eye cancer called uveal melanoma that hasn't spread to other parts of your body. You also need to be 18 years old or older. It's important that you are generally well enough to take part in the study, which means your body's organs are working properly, and you are able to sign a consent form and follow all the study instructions.

You would not be able to join this study if you have already had treatment for your uveal melanoma, or if there's evidence that your cancer has spread. Also, if there are other eye conditions that would make it difficult to properly check your vision, or if you have another type of cancer, you wouldn't be able to participate. Finally, if for some reason surgery to remove the eye is definitely needed, regardless of other treatments, then this study might not be suitable.

If you decide to take part in this study, you would first sign an informed consent form. Depending on which group you're in, you might take the study medication, darovasertib, for a period of time before your main treatment (either radiation or surgery). During this time, and after your main treatment, you'll have regular hospital visits. These visits will involve various tests and check-ups to monitor your health, how the medication is working, and progress of your eye condition. We'll be checking things like your vision and looking for any changes in the cancer. You will be followed up for a total of three years to assess long-term outcomes. The study team will explain the full schedule of visits and assessments in detail if you are considering joining.